Skip to main content

Table 4 Results of subgroup analysis of pooled hazard ratios of PFS of patients

From: Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Stratified analysis

No. of studies

Pooled HR (95% CI)

P‐value

Heterogeneity

I2 (%)

PQ

Cancer type

 RCC

4

1.52 (0.99, 2.31)

0.050

91

< 0.001

 PC

1

11.8 (5.6, 24.87)

< 0.001

NA

NA

 Unclear

2

1.6 (1.23, 2.07)

< 0.001

0

0.900

Urothelial cancer

2

1.6 (1.23, 2.07)

< 0.001

0

0.900

Non urothelial cancer

5

2.31 (1.23, 3.69)

0.007

95

< 0.001

Treatment

 Surgery

2

1.16 (0.8, 1.7)

0.430

62

0.110

 Non surgery

4

2.65 (1.53, 4.58)

< 0.001

88

< 0.001

 Mix

1

1.43 (0.89, 2.3)

0.140

NA

NA

Study type

 Prospective

1

1.43 (0.89, 2.3)

0.140

NA

NA

 Retrospective

6

2.03 (1.29, 3.2)

0.002

94

< 0.001

Analysis

 Multivariate

5

1.93 (1.14, 3.29)

0.010

93

< 0.001

 Univariate

2

1.91 (1.53, 2.38)

< 0.001

0

0.550

  1. CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index